Member Info for inanaco

your post .......... clearly a rec for a vaccine that offers little immunity ....

"""it may be, as with the monkeys, it prevents development of pneumonia and lessens the symptoms so that they may be no worse than a mild cold. As mentioned before, this vaccine should be safe for the elderly and those who are vulnerable due to pre-existing conditions - there are many people, including children and the elderly with pre-existing conditions who can see no prospect of a return to normal life due to the risk of COVID-19 and complete social isolation is no life at all. In the short term, if we get no more than a vaccine that lessens the symptoms, it would allow the country to return to normality while we wait for the second wave of vaccines and hopefully Scancell will be part of that. """

that is your words not mine

"we wait for the second wave of vaccines and hopefully Scancell will be part of that"" 9.10

if you asked which platform is the most efficient to use in the presentation of the Covid targets

oxford v scancell

immunobody would win based on data already presented

is that a post to me ?

bashing ... ?

data posted .... with explanations ...

and indeed you did REC. giving a poor vaccine while a better one is developed ... that is going out on a limb

"""it may be, as with the monkeys, it prevents development of pneumonia and lessens the symptoms so that they may be no worse than a mild cold. As mentioned before, this vaccine should be safe for the elderly and those who are vulnerable due to pre-existing conditions - there are many people, including children and the elderly with pre-existing conditions who can see no prospect of a return to normal life due to the risk of COVID-19 and complete social isolation is no life at all. In the short term, if we get no more than a vaccine that lessens the symptoms, it would allow the country to return to normality while we wait for the second wave of vaccines and hopefully Scancell will be part of that. """

you keep adding things that i have not posted ...

"Also it's not a race to find the one and only vaccine - I suspect/hope there will be several."

and you are making assumptions that it will work in the old ...

as Ruck would say

"Not proven" ... to me .. LOL

its so strange that you dismiss my take on CD8 t cells interacting with Keytruda ... that i cannot see how it could fail

yet ... you are prepared to go out on a limb ... for what appears to be a very poor immune response in primates ...

bermuda

""We know it's a new virus and the reason why Oxford were able to move so quickly is because they had an existing vaccine which they had developed as a vehicle for vaccines against other infectious diseases including coronaviruses.""

mmmmmm but the flu version failed and the cancer version barely worked which i highlighted weeks ago

Bermuda i understand why you wish to defend the oxford group, and as you have seen my posts today are not about the funding of ........ but even if it was it would be based on the "level playing field principle"

i would also point out a vaccine gives you "confidence" ...

if you are 80 and had the flu vaccine .. you are happy to mix with runny nose children etc ...

if your 80 with a poor covid vaccine it could be a death warrant

Ivy its not a mutation of SARS or MERS ...

"""latest strain"""

its a new virus ..... which will develop its own "strains "

which by the way has nothing to do with the target .......... viral or oncology

its how you deliver the target to the immune system ... to illicit the type of response that you need

Ivy you have missed the point they are still developing the platform on the job ............

Strategies to increase neutralising antibody seroconversion include a two-dose regimen, and investigations for this hypothesis are underway.

its a new virus ....

bermuda

You need proof that the platform can deliver ........

as you have seen these labs have found the target straight away .. so that area it appears is not to be difficult

compared to the discovery of cancer target antigens for instance

so as Lindy has done with Moditope ... which took 4 years to develop the most efficient way to present those peptides to the immune system its all about getting that bit right

immunobody has over 10 years experience of presenting to the immune system ...

ChAdOx1 MERS was able to elicit neutralising antibodies against live MERS-CoV in 44% of participants receiving the high dose.

Correlates of protection for MERS-CoV are currently unknown. Neutralising antibodies targeting different epitopes of the spike glycoprotein have been associated with protection against MERS-CoV challenge in animal models.30 Here, we demonstrated that a single dose of ChAdOx1 MERS was able to elicit neutralising antibodies against live MERS-CoV in 44% of participants receiving the high dose. Between 71% and 79% of all participants produced neutralising antibodies in assays using pseudotyped lentiviruses expressing the spike glycoprotein from three different strains of MERS-CoV. Despite differences in methodology, there was a strong positive correlation between neutralising antibodies from pseudotyped viruses and neutralising antibodies obtained from the live virus assay in the high-dose group. Strategies to increase neutralising antibody seroconversion include a two-dose regimen, and investigations for this hypothesis are underway.

""Agree Bermuda that Oxford were much further down the track than any other approach and the MERS experience would position it well""

its a new Virus ...

The platform is what generates the immune response its the way it engages the immune system to create the profile

the new target is inserted which in this case the spike

thus they are not as advanced as you think they are ... its an illusion

KEYTRUDA 2019 Worldwide Sales Grew 55% to $11.1 Billion

so my advice is simple ....

keytruda has the sales ............

and we are synergistic

Ruck i will remind you what you posted
As for impatience, I may have felt some 5/6 years ago into an investment I thought would bare fruit after 3/4 years but that’s long gone now. I’ve been waiting so long now I am past caring. It may come good but if it doesn’t who cares? Well not me anyway.

but then you retracted that .......... for this

TF, actually, in the cold light of day I withdraw that comment, lIke you, I’m NOT past caring. I may be less concerned about losing money as there’s not so much left to lose!
But I do care PASSIONATELY about the success of Scancell’s treatments for cancer, covid and anything else. I suspect, these WILL ultimately succeed but the cost of getting there will not result in the scale of return many of us hoped for when we first invested. This new reality was quite evident amongst the attendees at the AGM.

but the one thing you are missing is what will trigger the market ....

Moderna has just done it with a $5 billion rise in Mcap ..........

it does happen

apologies .. ""My last buy was three years ago at 10p as Inan likes to remind everyone periodically for some reason.""

you mean the sp has not yet climbed to your last buy at 10p ... Ruck some two years ago, and you did not average down in the sub 4p region ... still ... i am sure it will hit the 10p mark soon

scancell is developing modi2 ...

but first we need to crack that conjugate epitope ...

modi1 has 3 ... 2 are made, 1 missing in action

it will be sorted ...

if we can produce not just an antibody response which will subside over time .. but a full adaptive response

our vaccine will outperform spike only vaccines ..

$5 billion rise ........ is that enough capital growth ?